Shopping Cart
Total:

$0.00

Items:

0

Checkout View Cart
Your cart is empty
Keep Shopping

Dual Immunotherapy Improves DFS in Resectable Kidney Cancer



(MedPage Today) — SAN FRANCISCO — Adjuvant durvalumab (Imfinzi) and tremelimumab (Imjudo) improved disease-free survival (DFS) in a phase III trial of resectable renal cell carcinoma (RCC), but researchers here said the regimen’s impact on…



Source link

0
Show Comments (0) Hide Comments (0)
0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments